Commission Regulation (EC) No 1646/2004 of 20 September 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance)
EU Regulation No 1646/2004 · Adopted 20 September 2004 · Extends to United Kingdom
Commission Regulation (EC) No 1646/2004
of 20 September 2004
amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin
(Text with EEA relevance)
THE COMMISSION OF THE EUROPEAN COMMUNITIES,
Having regard to the Treaty establishing the European Community,
Having regard to Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal originf1, and in particular Articles 6, 7 and 8 thereof;
Whereas:
(1)
In accordance with Regulation (EEC) No 2377/90, maximum residue limits must be established progressively for all pharmacologically active substances which are used within the Community in veterinary medicinal products intended for administration to food-producing animals.
(2)
Maximum residue limits should be established only after the examination within the Committee for Veterinary Medicinal Products of all the relevant information concerning the safety of residues of the substance concerned for the consumer of foodstuffs of animal origin and the impact of residues on the industrial processing of foodstuffs.
(3)
In establishing maximum residue limits for residues of veterinary medicinal products in foodstuffs of animal origin, it is necessary to specify the animal species in which residues may be present, the levels which may be present in each of the relevant meat tissues obtained from the treated animal (target tissue) and the nature of the residue which is relevant for the monitoring of residues (marker residue).
(4)
In view of the reduced availability of veterinary medicinal products for certain food-producing speciesf2, maximum residue limits may be established by methods of extrapolation from maximum residue limits set for other species on a strictly scientific basis.
(5)
For the control of residues, as provided for in appropriate Community legislation, maximum residue limits should usually be established for the target tissues of liver or kidney. However, the liver and kidney are frequently removed from carcasses moving in international trade, and maximum residue limits should therefore also always be established for muscle or fat tissues.
(6)
In the case of veterinary medicinal products intended for use in laying birds, lactating animals or honey bees, maximum residue limits must also be established for eggs, milk or honey.
(7)
Albendazole, Febantel, Fenbendazole, Oxfendazole, Thiabendazole, Oxyclozanide, Amitraz, Cypermethrin, Deltamethrin and Dexamethasone should be inserted into Annex I to Regulation (EEC) No 2377/90;
(8)
An adequate period should be allowed before the entry into force of this Regulation in order to allow Member States to make any adjustment which may be necessary to the authorisations to place the veterinary medicinal products concerned on the market which have been granted in accordance with Directive 2001/82/ECf3 of the European Parliament and of the Council to take account of the provisions of this Regulation.
(9)
The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products.
HAS ADOPTED THE FOLLOWING REGULATION:
Annotations to the whole text
Footnotes
- f1
-
OJ L 224, 18.8.1990, p. 1. Regulation as last amended by Commission Regulation (EC) No 1101/2004 (OJ L 211, 12.6.2004, p. 3).
- f2
-
Availability of veterinary medicinal products Communication from the Commission to the Council and the European Parliament COM(2000) 806 final.
- f3
-
OJ L 311, 28.11.2001, p. 1. Directive as last amended by Directive 2004/28/EC (OJ L 136, 30.4.2004, p. 58).
Contents
- 1Article 1
- 2Article 2
- Signature
- Annex Annex
- 2Division 2
- 2.1Division 2.1
- 2.1.3Division 2.1.3
- 2.1.1Division 2.1.1
- 2.2Division 2.2
- 2.2.2Division 2.2.2
- 2.2.3Division 2.2.3
- 5Division 5
- 5.1Division 5.1
1
Annex I to Regulation (EEC) No 2377/90 is hereby amended as set out in the Annex hereto.
2
This Regulation shall enter into force on the third day following its publication in the Official Journal of the European Union.
It shall apply from the sixtieth day following its publication.
Signature
This Regulation shall be binding in its entirety and directly applicable in all Member States.
The following substance(s) is(are) inserted in Annex I:
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues ‘Albendazole Sum of albendazole sulphoxide, albendazole sulphone, and albendazole 2-amino sulphone, expressed as albendazole All ruminants 100 μg/kg Muscle 100 μg/kg Fat 1 000 μg/kg Liver 500 μg/kg Kidney 100 μg/kg Milk Febantel Sum of extractable residues which may be oxidised to oxfendazole sulphone All ruminants 50 μg/kg Muscle 50 μg/kg Fat 500 μg/kg Liver 50 μg/kg Kidney 10 μg/kg Milk Fenbendazole Sum of extractable residues which may be oxidised to oxfendazole sulphone All ruminants 50 μg/kg Muscle 50 μg/kg Fat 500 μg/kg Liver 50 μg/kg Kidney 10 μg/kg Milk Oxfendazole Sum of extractable residues which may be oxidised to oxfendazole sulphone All ruminants 50 μg/kg Muscle 50 μg/kg Fat 500 μg/kg Liver 50 μg/kg Kidney 10 μg/kg Milk Thiabendazole Sum of thiabendazole and 5-hydroxythiabendazole Caprine 100 μg/kg Muscle 100 μg/kg Fat 100 μg/kg Liver 100 μg/kg Kidney 100 μg/kg Milk’
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues ‘Oxyclozanide Oxyclozanide All ruminants 20 μg/kg Muscle 20 μg/kg Fat 500 μg/kg Liver 100 μg/kg Kidney 10 μg/kg Milk’
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues ‘Amitraz Sum of amitraz and all metabolites containing the 2,4-dimethylaniline moiety, expressed as amitraz Caprine 200 μg/kg Fat 100 μg/kg Liver 200 μg/kg Kidney 10 μg/kg Milk’
Further provisions in Commission Directive 98/82/EC are to be observed (OJ L290, 29.10.1998, p. 25).’
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues ‘Cypermethrin Cypermethrin (sum of isomers) All ruminants 20 μg/kg Muscle 200 μg/kg Fat 20 μg/kg Liver 20 μg/kg Kidney 20 μg/kg Milkf1 Deltamethrin Deltamethrin All ruminants 10 μg/kg Muscle 50 μg/kg Fat 10 μg/kg Liver 10 μg/kg Kidney 20 μg/kg Milk
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues ‘Dexamethasone Dexamethasone Caprine 0,75 μg/kg Muscle 2 μg/kg Liver 0,75 μg/kg Kidney 0,3 μg/kg Milk’
2
Antiparasitic agents
2.1
Agents acting against endoparasites
2.1.3
Benzimidazoles and pro-benzimidazoles
2.1.1X1
Salicylanilides
2.2
Agents acting against ectoparasites
2.2.2
Formamidines
2.2.3
Pyrethroids
5
Corticoids
5.1
Glucocorticoids